Literature DB >> 10381359

The length of polyglutamine tract, its level of expression, the rate of degradation, and the transglutaminase activity influence the formation of intracellular aggregates.

T de Cristofaro1, A Affaitati, L Cariello, E V Avvedimento, S Varrone.   

Abstract

A common feature of CAG-expansion neurodegenerative diseases is the presence of intranuclear aggregates in neuronal cells. We have used a synthetic fusion protein containing at the NH2 terminus the influenza hemoagglutinin epitope (HA), a polyglutamine stretch (polyQ) of various size (17, 36, 43 CAG) and a COOH tail encoding the green fluorescent protein (GFP). The fusion proteins were expressed in COS-7 and neuroblastoma SK-N-BE cells. We found that the formation of aggregates largely depends on the length of polyglutamine tracts and on the levels of expression of the fusion protein. Moreover, transglutaminase overexpression caused an increase of insoluble aggregates only in cells expressing the mutant expanded protein. Conversely, treatment of cells with cystamine, a transglutaminase inhibitor, reduced the percentage of aggregates. We found also that the inhibition of the proteasome ubiquitin-dependent degradation increased the formation of intranuclear aggregates. These data suggest that length of polyglutamine tract, its expression, unbalance between cellular transglutaminase activity, and the ubiquitin-degradation pathway are key factors in the formation of intranuclear aggregates. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10381359     DOI: 10.1006/bbrc.1999.0851

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Therapeutic effects of cystamine in a murine model of Huntington's disease.

Authors:  Alpaslan Dedeoglu; James K Kubilus; Thomas M Jeitner; Samantha A Matson; Misha Bogdanov; Neil W Kowall; Wayne R Matson; Arthur J L Cooper; Rajiv R Ratan; M Flint Beal; Steven M Hersch; Robert J Ferrante
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

2.  Structural characterization of transglutaminase-catalyzed cross-linking between glyceraldehyde 3-phosphate dehydrogenase and polyglutamine repeats.

Authors:  Margherita Ruoppolo; Stefania Orrù; Simona Francese; Ivana Caputo; Carla Esposito
Journal:  Protein Sci       Date:  2003-01       Impact factor: 6.725

3.  Side-chain interactions determine amyloid formation by model polyglutamine peptides in molecular dynamics simulations.

Authors:  Alexander J Marchut; Carol K Hall
Journal:  Biophys J       Date:  2006-03-24       Impact factor: 4.033

4.  Identification of tissue transglutaminase-reactive lysine residues in glyceraldehyde-3-phosphate dehydrogenase.

Authors:  Stefania Orru; Margherita Ruoppolo; Simona Francese; Luigi Vitagliano; Gennaro Marino; Carla Esposito
Journal:  Protein Sci       Date:  2002-01       Impact factor: 6.725

5.  Oligomeric and polymeric aggregates formed by proteins containing expanded polyglutamine.

Authors:  S Iuchi; G Hoffner; P Verbeke; P Djian; H Green
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-18       Impact factor: 11.205

Review 6.  The ubiquitin-proteasome system in retinal health and disease.

Authors:  Laura Campello; Julián Esteve-Rudd; Nicolás Cuenca; José Martín-Nieto
Journal:  Mol Neurobiol       Date:  2013-01-22       Impact factor: 5.590

Review 7.  Transglutaminase 2 inhibitors and their therapeutic role in disease states.

Authors:  Matthew Siegel; Chaitan Khosla
Journal:  Pharmacol Ther       Date:  2007-05-13       Impact factor: 12.310

8.  Tissue transglutaminase does not contribute to the formation of mutant huntingtin aggregates.

Authors:  W Chun; M Lesort; J Tucholski; C A Ross; G V Johnson
Journal:  J Cell Biol       Date:  2001-04-02       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.